Search

Your search keyword '"Rathkopf, Dana E."' showing total 382 results
Start Over Author "Rathkopf, Dana E." Publication Year Range Last 50 years
382 results on '"Rathkopf, Dana E."'

1. Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer

Author

Truong, Hong, Breen, Kelsey, Nandakumar, Subhiksha, Sjoberg, Daniel D., Kemel, Yelena, Mehta, Nikita, Lenis, Andrew T., Reisz, Peter A., Carruthers, Jessica, Benfante, Nicole, Joseph, Vijai, Khurram, Aliya, Gopalan, Anuradha, Fine, Samson W., Reuter, Victor E., Vickers, Andrew J., Birsoy, Ozge, Liu, Ying, Walsh, Michael, Latham, Alicia, Mandelker, Diana, Stadler, Zsofia K., Pietzak, Eugene, Ehdaie, Behfar, Touijer, Karim A., Laudone, Vincent P., Slovin, Susan F., Autio, Karen A., Danila, Daniel C., Rathkopf, Dana E., Eastham, James A., Chen, Yu, Morris, Michael J., Offit, Kenneth, Solit, David B., Scher, Howard I., Abida, Wassim, Robson, Mark E., and Carlo, Maria I.

Published
2023
Full Text
View/download PDF

2. LIBERTAS: A degendered and transgender-inclusive phase 3 study of apalutamide (APA) plus intermittent vs continuous androgen deprivation therapy (ADT) in participants (pts) with metastatic hormone-sensitive prostate cancer (mHSPC).

Author

Azad, Arun, primary, Musto, Clark, additional, Netanel, Shir, additional, Zhang, Tian, additional, Rathkopf, Dana E., additional, Badillo, Marco Antonio, additional, Dong, Qiang, additional, Morgans, Alicia K., additional, Runcie, Karie, additional, Dos Santos, Alex, additional, Bhaumik, Amitabha, additional, Mundle, Suneel, additional, McCarthy, Sharon, additional, Lopez- Gitlitz, Angela Mennicke, additional, Batavia, Ashita S., additional, Sanchez, Daniel P., additional, Wildgust, Mark A., additional, and Agarwal, Neeraj, additional

Published
2024
Full Text
View/download PDF

3. DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway

Author

Kothari, Vishal, Goodwin, Jonathan F, Zhao, Shuang G, Drake, Justin M, Yin, Yi, Chang, S Laura, Evans, Joseph R, Wilder-Romans, Kari, Gabbara, Kristina, Dylgjeri, Emanuela, Chou, Jonathan, Sun, Grace, Tomlins, Scott A, Mehra, Rohit, Hege, Kristen, Filvaroff, Ellen H, Schaeffer, Edward M, Karnes, R Jeffrey, Quigley, David A, Rathkopf, Dana E, He, Housheng H, Speers, Corey, Spratt, Daniel E, Gilbert, Luke A, Ashworth, Alan, Chinnaiyan, Arul M, Raj, Ganesh V, Knudsen, Karen E, and Feng, Felix Y

Subjects
Prostate Cancer, Urologic Diseases, Genetics, Aging, Cancer, 2.1 Biological and endogenous factors, Aetiology, Animals, Biomarkers, Tumor, Cell Line, Tumor, Cell Movement, DNA-Activated Protein Kinase, Disease Models, Animal, Disease Progression, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Gene Knockdown Techniques, Heterografts, Humans, Male, Mice, Neoplasm Metastasis, Phenotype, Prostatic Neoplasms, Protein Binding, RNA, Small Interfering, Transcription, Genetic, Wnt Signaling Pathway, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PURPOSE:Protein kinases are known to play a prominent role in oncogenic progression across multiple cancer subtypes, yet their role in prostate cancer progression remains underexplored. The purpose of this study was to identify kinases that drive prostate cancer progression.Experimental Design: To discover kinases that drive prostate cancer progression, we investigated the association between gene expression of all known kinases and long-term clinical outcomes in tumor samples from 545 patients with high-risk disease. We evaluated the impact of genetic and pharmacologic inhibition of the most significant kinase associated with metastatic progression in vitro and in vivo. RESULTS:DNA-dependent protein kinase (DNAPK) was identified as the most significant kinase associated with metastatic progression in high-risk prostate cancer. Inhibition of DNAPK suppressed the growth of both AR-dependent and AR-independent prostate cancer cells. Gene set enrichment analysis nominated Wnt as the top pathway associated with DNAPK. We found that DNAPK interacts with the Wnt transcription factor LEF1 and is critical for LEF1-mediated transcription. CONCLUSIONS:Our data show that DNAPK drives prostate cancer progression through transcriptional regulation of Wnt signaling and is an attractive therapeutic target in aggressive prostate cancer.

Published
2019

4. Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy

Author

Autio, Karen A., Antonarakis, Emmanuel S., Mayer, Tina M., Shevrin, Daniel H., Stein, Mark N., Vaishampayan, Ulka N., Morris, Michael J., Slovin, Susan F., Heath, Elisabeth I., Tagawa, Scott T., Rathkopf, Dana E., Milowsky, Matthew I., Harrison, Michael R., Beer, Tomasz M., Balar, Arjun V., Armstrong, Andrew J., George, Daniel J., Paller, Channing J., Apollo, Arlyn, Danila, Daniel C., Graff, Julie N., Nordquist, Luke, Dayan Cohn, Erica S., Tse, Kin, Schreiber, Nicole A., Heller, Glenn, and Scher, Howard I.

Published
2021
Full Text
View/download PDF

5. FIGURE 1 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

6. Data from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

7. Data from Marital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer

Author

Chen, Naiyu, primary, McGrath, Colleen B., primary, Ericsson, Caroline I., primary, Vaselkiv, Jane B., primary, Rencsok, Emily M., primary, Stopsack, Konrad H., primary, Guard, Hannah E., primary, Autio, Karen A., primary, Rathkopf, Dana E., primary, Enting, Deborah, primary, Bitting, Rhonda L., primary, Mateo, Joaquin, primary, Githiaka, Charles W., primary, Chi, Kim N., primary, Cheng, Heather H., primary, Davis, Ian D., primary, Anderson, Simon G., primary, Badal, Simone Ann Marie, primary, Bjartell, Anders, primary, Russnes, Kjell M., primary, Heath, Elisabeth I., primary, Pomerantz, Mark M., primary, Henegan, John C., primary, Hyslop, Terry, primary, Esteban, Emilio, primary, Omlin, Aurelius, primary, McDermott, Ray, primary, Fay, Andre P., primary, Popoola, Ademola Alabi, primary, Ragin, Camille, primary, Nowak, Joel, primary, Gerke, Travis, primary, Kantoff, Philip W., primary, George, Daniel J., primary, Penney, Kathryn L., primary, and Mucci, Lorelei A., primary

Published
2024
Full Text
View/download PDF

8. Supplementary Table 1. from Marital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer

Author

Chen, Naiyu, primary, McGrath, Colleen B., primary, Ericsson, Caroline I., primary, Vaselkiv, Jane B., primary, Rencsok, Emily M., primary, Stopsack, Konrad H., primary, Guard, Hannah E., primary, Autio, Karen A., primary, Rathkopf, Dana E., primary, Enting, Deborah, primary, Bitting, Rhonda L., primary, Mateo, Joaquin, primary, Githiaka, Charles W., primary, Chi, Kim N., primary, Cheng, Heather H., primary, Davis, Ian D., primary, Anderson, Simon G., primary, Badal, Simone Ann Marie, primary, Bjartell, Anders, primary, Russnes, Kjell M., primary, Heath, Elisabeth I., primary, Pomerantz, Mark M., primary, Henegan, John C., primary, Hyslop, Terry, primary, Esteban, Emilio, primary, Omlin, Aurelius, primary, McDermott, Ray, primary, Fay, Andre P., primary, Popoola, Ademola Alabi, primary, Ragin, Camille, primary, Nowak, Joel, primary, Gerke, Travis, primary, Kantoff, Philip W., primary, George, Daniel J., primary, Penney, Kathryn L., primary, and Mucci, Lorelei A., primary

Published
2024
Full Text
View/download PDF

9. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study

Author

Saad, Fred, Efstathiou, Eleni, Attard, Gerhardt, Flaig, Thomas W, Franke, Fabio, Goodman, Oscar B, Jr, Oudard, Stéphane, Steuber, Thomas, Suzuki, Hiroyoshi, Wu, Daphne, Yeruva, Kesav, De Porre, Peter, Brookman-May, Sabine, Li, Susan, Li, Jinhui, Thomas, Shibu, Bevans, Katherine B, Mundle, Suneel D, McCarthy, Sharon A, and Rathkopf, Dana E

Published
2021
Full Text
View/download PDF

10. FIGURE 2 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

11. Supplementary Table S4 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

12. Supplementary Figure S2 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

13. TABLE 1 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

14. TABLE 3 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

15. TABLE 4 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

16. TABLE 2 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

17. Marital status, living arrangement, and survival among individuals with advanced prostate cancer in the International Registry for Men with Advanced Prostate Cancer

Author

Chen, Naiyu, primary, McGrath, Colleen B., additional, Ericsson, Caroline I., additional, Vaselkiv, Jane B., additional, Rencsok, Emily M., additional, Stopsack, Konrad H., additional, Guard, Hannah E., additional, Autio, Karen A., additional, Rathkopf, Dana E., additional, Enting, Deborah, additional, Bitting, Rhonda L., additional, Mateo, Joaquin, additional, Githiaka, Charles Waihenya., additional, Chi, Kim N., additional, Cheng, Heather H., additional, Davis, Ian D., additional, Anderson, Simon G., additional, Badal, Simone Ann Marie., additional, Bjartell, Anders, additional, Russnes, Kjell M., additional, Heath, Elisabeth I., additional, Pomerantz, Mark M., additional, Henegan, John C., additional, Hyslop, Terry, additional, Esteban, Emilio, additional, Omlin, Aurelius, additional, McDermott, Ray, additional, Fay, Andre P., additional, Popoola, Ademola Alabi., additional, Ragin, Camille, additional, Nowak, Joel, additional, Gerke, Travis, additional, Kantoff, Philip W., additional, George, Daniel J., additional, Penney, Kathryn L., additional, and Mucci, Lorelei A., additional

Published
2024
Full Text
View/download PDF

18. Supplementary Methods S1 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

20. A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer

Author

Zhao, Shuang G., Sperger, Jamie M., Schehr, Jennifer L., McKay, Rana R., Emamekhoo, Hamid, Singh, Anupama, Schultz, Zachery D., Bade, Rory M., Stahlfeld, Charlotte N., Gilsdorf, Cole S., Hernandez, Camila I., Wolfe, Serena K., Mayberry, Richel D., Krause, Hannah M., Bootsma, Matt, Helzer, Kyle T., Rydzewski, Nicholas, Bakhtiar, Hamza, Shi, Yue, Blitzer, Grace, Kyriakopoulos, Christos E., Kosoff, David, Wei, Xiao X., Floberg, John, Sethakorn, Nan, Sharifi, Marina, Harari, Paul M., Huang, Wei, Beltran, Himisha, Choueiri, Toni K., Scher, Howard I., Rathkopf, Dana E., Halabi, Susan, Armstrong, Andrew J., Beebe, David J., Yu, Menggang, Sundling, Kaitlin E., Taplin, Mary-Ellen, and Lang, Joshua M.

Subjects
Prostate cancer -- Development and progression -- Prognosis, Tumor markers -- Genetic aspects -- Health aspects, Health care industry
Abstract

BACKGROUND. Neuroendocrine prostate cancer (NEPC) is an aggressive subtype, the presence of which changes the prognosis and management of metastatic prostate cancer. METHODS. We performed analytical validation of a Circulating Tumor Cell (CTC) multiplex RNA qPCR assay to identify the limit of quantification (LOQ) in cell lines, synthetic cDNA, and patient samples. We next profiled 116 longitudinal samples from a prospectively collected institutional cohort of 17 patients with metastatic prostate cancer (7 NEPC, 10 adenocarcinoma) as well as 265 samples from 139 patients enrolled in 3 adenocarcinoma phase II trials of androgen receptor signaling inhibitors (ARSIs). We assessed a NEPC liquid biomarker via the presence of neuroendocrine markers and the absence of androgen receptor (AR) target genes. RESULTS. Using the analytical validation LOQ, liquid biomarker NEPC detection in the longitudinal cohort had a per- sample sensitivity of 51.35% and a specificity of 91.14%. However, when we incorporated the serial information from multiple liquid biopsies per patient, a unique aspect of this study, the per-patient predictions were 100% accurate, with a receiver- operatingcurve (ROC) AUC of 1. In the adenocarcinoma ARSI trials, the presence of neuroendocrine markers, even while AR target gene expression was retained, was a strong negative prognostic factor. CONCLUSION. Our analytically validated CTC biomarker can detect NEPC with high diagnostic accuracy when leveraging serial samples that are only feasible using liquid biopsies. Patients with expression of NE genes while retaining AR- target gene expression may indicate the transition to neuroendocrine differentiation, with clinical characteristics consistent with this phenotype. FUNDING. NIH (DP2 OD030734, 1UH2CA260389, R01CA247479, and P30 CA014520), Department of Defense (PC190039 and PC200334), and Prostate Cancer Foundation (Movember Foundation--PCF Challenge Award)., Introduction The majority of prostate cancers are histologically classified as adenocarcinomas. Prostate adenocarcinoma is driven by androgens, expresses prostate-specific antigen (PSA) and other androgen receptor (AR) target genes, and responds [...]

Published
2022
Full Text
View/download PDF

23. Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)

Author

Rathkopf, Dana E, Smith, Matthew R, de Bono, Johann S, Logothetis, Christopher J, Shore, Neal D, de Souza, Paul, Fizazi, Karim, Mulders, Peter FA, Mainwaring, Paul, Hainsworth, John D, Beer, Tomasz M, North, Scott, Fradet, Yves, Van Poppel, Hendrik, Carles, Joan, Flaig, Thomas W, Efstathiou, Eleni, Yu, Evan Y, Higano, Celestia S, Taplin, Mary-Ellen, Griffin, Thomas W, Todd, Mary B, Yu, Margaret K, Park, Youn C, Kheoh, Thian, Small, Eric J, Scher, Howard I, Molina, Arturo, Ryan, Charles J, and Saad, Fred

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Prostate Cancer, Urologic Diseases, Rehabilitation, Aging, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Abiraterone Acetate, Aged, Androstenes, Antineoplastic Agents, Hormonal, Antineoplastic Combined Chemotherapy Protocols, Cytochrome P-450 Enzyme Inhibitors, Disease Progression, Disease-Free Survival, Double-Blind Method, Drug Administration Schedule, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Metastasis, Neoplasms, Hormone-Dependent, Prednisone, Proportional Hazards Models, Prostatic Neoplasms, Castration-Resistant, Risk Factors, Steroid 17-alpha-Hydroxylase, Time Factors, Treatment Outcome, Abiraterone acetate, Chemotherapy-naive, Efficacy, Metastatic castration-resistant, prostate cancer, Safety, Metastatic castration-resistant prostate cancer, Urology & Nephrology, Clinical sciences
Abstract

BackgroundAbiraterone acetate (an androgen biosynthesis inhibitor) plus prednisone is approved for treating patients with metastatic castration-resistant prostate cancer (mCRPC). Study COU-AA-302 evaluated abiraterone acetate plus prednisone versus prednisone alone in mildly symptomatic or asymptomatic patients with progressive mCRPC without prior chemotherapy.ObjectiveReport the prespecified third interim analysis (IA) of efficacy and safety outcomes in study COU-AA-302.Design, setting, and participantsStudy COU-AA-302, a double-blind placebo-controlled study, enrolled patients with mCRPC from April 2009 to June 2010. A total of 1088 patients were stratified by Eastern Cooperative Oncology Group performance status (0 vs 1).InterventionPatients were randomised 1:1 to abiraterone 1000mg plus prednisone 5mg twice daily by mouth versus prednisone.Outcome measurements and statistical analysisCo-primary end points were radiographic progression-free survival (rPFS) and overall survival (OS). Median times to event outcomes were estimated using the Kaplan-Meier method. Hazard ratios (HRs) and 95% confidence intervals (CIs) were derived using the Cox model, and treatment comparison used the log-rank test. The O'Brien-Fleming Lan-DeMets α-spending function was used for OS. Adverse events were summarised descriptively.Results and limitationsWith a median follow-up duration of 27.1 mo, improvement in rPFS was statistically significant with abiraterone treatment versus prednisone (median: 16.5 vs 8.2 mo; HR: 0.52 [95% CI, 0.45-0.61]; p2 yr.

Published
2014

24. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

Author

Beer, Tomasz M, Armstrong, Andrew J, Rathkopf, Dana E, Loriot, Yohann, Sternberg, Cora N, Higano, Celestia S, Iversen, Peter, Bhattacharya, Suman, Carles, Joan, Chowdhury, Simon, Davis, Ian D, de Bono, Johann S, Evans, Christopher P, Fizazi, Karim, Joshua, Anthony M, Kim, Choung-Soo, Kimura, Go, Mainwaring, Paul, Mansbach, Harry, Miller, Kurt, Noonberg, Sarah B, Perabo, Frank, Phung, De, Saad, Fred, Scher, Howard I, Taplin, Mary-Ellen, Venner, Peter M, and Tombal, Bertrand

Subjects
Urologic Diseases, Clinical Trials and Supportive Activities, Prostate Cancer, Clinical Research, Aging, Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adenocarcinoma, Administration, Oral, Androgen Receptor Antagonists, Antineoplastic Agents, Hormonal, Benzamides, Disease Progression, Double-Blind Method, Humans, Male, Neoplasm Metastasis, Nitriles, Phenylthiohydantoin, Prostatic Neoplasms, Radiography, Receptors, Androgen, Survival Analysis, PREVAIL Investigators, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundEnzalutamide is an oral androgen-receptor inhibitor that prolongs survival in men with metastatic castration-resistant prostate cancer in whom the disease has progressed after chemotherapy. New treatment options are needed for patients with metastatic prostate cancer who have not received chemotherapy, in whom the disease has progressed despite androgen-deprivation therapy.MethodsIn this double-blind, phase 3 study, we randomly assigned 1717 patients to receive either enzalutamide (at a dose of 160 mg) or placebo once daily. The coprimary end points were radiographic progression-free survival and overall survival.ResultsThe study was stopped after a planned interim analysis, conducted when 540 deaths had been reported, showed a benefit of the active treatment. The rate of radiographic progression-free survival at 12 months was 65% among patients treated with enzalutamide, as compared with 14% among patients receiving placebo (81% risk reduction; hazard ratio in the enzalutamide group, 0.19; 95% confidence interval [CI], 0.15 to 0.23; P

Published
2014

25. Marital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer.

Author

Naiyu Chen, McGrath, Colleen B., Ericsson, Caroline I., Vaselkiv, Jane B., Rencsok, Emily M., Stopsack, Konrad H., Guard, Hannah E., Autio, Karen A., Rathkopf, Dana E., Enting, Deborah, Bitting, Rhonda L., Mateo, Joaquin, Githiaka, Charles W., Chi, Kim N., Cheng, Heather H., Davis, Ian D., Anderson, Simon G., Badal, Simone Ann Marie, Bjartell, Anders, and Russnes, Kjell M.

Abstract

Background: Studies have shown improved survival among individuals with cancer with higher levels of social support. Few studies have investigated social support and overall survival (OS) in individuals with advanced prostate cancer in an international cohort. We investigated the associations of marital status and living arrangements with OS among individuals with advanced prostate cancer in the International Registry for Men with Advanced Prostate Cancer (IRONMAN). Methods: IRONMAN is enrolling participants diagnosed with advanced prostate cancer (metastatic hormone-sensitive prostate cancer, mHSPC; castration-resistant prostate cancer, CRPC) from 16 countries. Participants in this analysis were recruited between July 2017 and January 2023. Adjusting for demographics and tumor characteristics, the associations were estimated using Cox regression and stratified by disease state (mHSPC, CRPC), age (<70, =70 years), and continent of enrollment (North America, Europe, Other). Results: We included 2,119 participants with advanced prostate cancer, of whom 427 died during up to 5 years of follow-up (median 6 months). Two-thirds had mHSPC. Most were married/in a civil partnership (79%) and 6% were widowed. Very few married participants were living alone (1%), while most unmarried participants were living alone (70%). Married participants had better OS than unmarried participants [adjusted HR: 1.44; 95% confidence interval (CI): 1.02-2.02]. Widowed participants had the worst survival compared with married individuals (adjusted HR: 1.89; 95% CI: 1.22-2.94). Conclusions: Among those with advanced prostate cancer, unmarried and widowed participants had worse OS compared with married participants. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Apalutamide (APA) plus intermittent versus continuous androgen-deprivation therapy (ADT) in participants (pts) with metastatic castration-sensitive prostate cancer (mCSPC): LIBERTAS phase 3 study design.

Author

Azad, Arun, Badillo, Marco Antonio, Dong, Qiang, Morgans, Alicia K., Rathkopf, Dana E., Runcie, Karie, Zhang, Tian, Pruthi, Raj, Bhaumik, Amitabha, Mundle, Suneel, McCarthy, Sharon, Lopez- Gitlitz, Angela Mennicke, Whalen, Jennifer, Batavia, Ashita S., Musto, Clark, Netanel, Shir, Sanchez, Daniel P., and Agarwal, Neeraj

Published
2024
Full Text
View/download PDF

27. Post radical prostatectomy (RP) PSA outcomes following 6 versus 18 months of perioperative androgen receptor signaling inhibitors (ARSI) in men with localized high-risk prostate cancer: Results of Part 2 of a randomized phase 2 trial.

Author

McKay, Rana R., Xie, Wanling, Yang, Xiaoyu, Acosta, Andres, Rathkopf, Dana E., Laudone, Vincent Paul, Bubley, Glenn, Einstein, David Johnson, Chang, Peter, Wagner, Andrew, Kane, Christopher J., Preston, Mark A., Kilbridge, Kerry L., Chang, Steven Lee, Choudhury, Atish Dipankar, Pomerantz, Mark, Trinh, Quoc-Dien, Kibel, Adam S., and Taplin, Mary-Ellen

Published
2024
Full Text
View/download PDF

28. Patient-reported health-related quality of life (HRQoL) in the randomized FORMULA-509 trial of salvage radiotherapy and 6 months of GnRH agonist with either bicalutamide or abiraterone acetate plus prednisone (AAP) and apalutamide (Apa) after radical...

Author

Hoffman, Karen E., Nguyen, Paul L., Rathkopf, Dana E., Zurita, Amado J., Spratt, Daniel Eidelberg, Dess, Robert Timothy, Liauw, Stanley L., Szmulewitz, Russell Zelig, Einstein, David Johnson, Bubley, Glenn, Yu, James B., An, Yi, Wong, Anthony C., Feng, Felix Y, McKay, Rana R., Rose, Brent S., Shin, Kee-Young, Kibel, Adam S., Taplin, Mary-Ellen, and Kollmeier, Marisa

Published
2024
Full Text
View/download PDF

29. First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Author

Rathkopf, Dana E., Patel, Manish R., Choudhury, Atish Dipankar, Rasco, Drew W., Lakhani, Nehal J., Hawley, Jessica E., Aparicio, Ana, Narayan, Vivek, Srinivas, Sandy, Runcie, Karie, Emamekhoo, Hamid, Reichert, Zachery R, Carducci, Michael Anthony, Wells, Amber L., Liu, Can, Kandimalla, Raju, Wu, Jiaju, Nguyen, Marie Huong, Pourdehnad, Michael, and Armstrong, Andrew J.

Published
2024
Full Text
View/download PDF

30. Patient-reported outcomes (PRO) in patients (pts) with BRCA1/2 -altered metastatic castration-resistant prostate cancer (mCRPC) receiving niraparib (NIRA) with abiraterone acetate and prednisone (AAP): Results from MAGNITUDE study.

Author

Rathkopf, Dana E., Roubaud, Guilhem, Chi, Kim N., Efstathiou, Eleni, Attard, Gerhardt, Olmos, David, Small, Eric J., Saad, Marniza, Castro, Elena, Kim, Won, Wu, Daphne, Bertzos, Kristi, Dibaj, Shiva, Zhang, Jenny, Francis, Peter St. John, and Smith, Matthew Raymond

Published
2024
Full Text
View/download PDF

31. Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

Author

Ryan, Charles J, Smith, Matthew R, de Bono, Johann S, Molina, Arturo, Logothetis, Christopher J, de Souza, Paul, Fizazi, Karim, Mainwaring, Paul, Piulats, Josep M, Ng, Siobhan, Carles, Joan, Mulders, Peter FA, Basch, Ethan, Small, Eric J, Saad, Fred, Schrijvers, Dirk, Van Poppel, Hendrik, Mukherjee, Som D, Suttmann, Henrik, Gerritsen, Winald R, Flaig, Thomas W, George, Daniel J, Yu, Evan Y, Efstathiou, Eleni, Pantuck, Allan, Winquist, Eric, Higano, Celestia S, Taplin, Mary-Ellen, Park, Youn, Kheoh, Thian, Griffin, Thomas, Scher, Howard I, and Rathkopf, Dana E

Subjects
Clinical Research, Cancer, Prostate Cancer, Urologic Diseases, Aging, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Abiraterone Acetate, Androstadienes, Antineoplastic Agents, Hormonal, Antineoplastic Combined Chemotherapy Protocols, Disease-Free Survival, Double-Blind Method, Humans, Male, Neoplasm Metastasis, Prednisone, Prostatic Neoplasms, Survival Analysis, COU-AA-302 Investigators, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundAbiraterone acetate, an androgen biosynthesis inhibitor, improves overall survival in patients with metastatic castration-resistant prostate cancer after chemotherapy. We evaluated this agent in patients who had not received previous chemotherapy.MethodsIn this double-blind study, we randomly assigned 1088 patients to receive abiraterone acetate (1000 mg) plus prednisone (5 mg twice daily) or placebo plus prednisone. The coprimary end points were radiographic progression-free survival and overall survival.ResultsThe study was unblinded after a planned interim analysis that was performed after 43% of the expected deaths had occurred. The median radiographic progression-free survival was 16.5 months with abiraterone-prednisone and 8.3 months with prednisone alone (hazard ratio for abiraterone-prednisone vs. prednisone alone, 0.53; 95% confidence interval [CI], 0.45 to 0.62; P

Published
2013

32. External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer

Author

Halabi, Susan, primary, Yang, Qian, additional, Roy, Akash, additional, Luo, Bin, additional, Araujo, John C., additional, Logothetis, Christopher, additional, Sternberg, Cora N., additional, Armstrong, Andrew J., additional, Carducci, Michael A., additional, Chi, Kim N., additional, de Bono, Johann S., additional, Petrylak, Daniel P., additional, Fizazi, Karim, additional, Higano, Celestia S., additional, Morris, Michael J., additional, Rathkopf, Dana E., additional, Saad, Fred, additional, Ryan, Charles J., additional, Small, Eric J., additional, and Kelly, William Kevin, additional

Published
2023
Full Text
View/download PDF

33. Abstract 6489: Marital status, living arrangement, and overall survival among individuals with advanced prostate cancer in the IRONMAN cohort

Author

Chen, Naiyu, primary, McGrath, Colleen B., additional, Ericsson, Caroline I., additional, Vaselkiv, Jane B., additional, Sodipo, Michelle O., additional, Rencsok, Emily M., additional, Stopsack, Konrad H., additional, George, Daniel J., additional, Autio, Karen A., additional, Rathkopf, Dana E., additional, Penney, Kathryn L., additional, and Mucci, Lorelei A., additional

Published
2023
Full Text
View/download PDF

35. Supplementary Figure from A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors

Author

Choudhury, Atish D., primary, Higano, Celestia S., primary, de Bono, Johann S., primary, Cook, Natalie, primary, Rathkopf, Dana E., primary, Wisinski, Kari B., primary, Martin-Liberal, Juan, primary, Linch, Mark, primary, Heath, Elisabeth I., primary, Baird, Richard D., primary, García-Carbacho, Javier, primary, Quintela-Fandino, Miguel, primary, Barry, Simon T., primary, de Bruin, Elza C., primary, Colebrook, Steve, primary, Hawkins, George, primary, Klinowska, Teresa, primary, Maroj, Brijesh, primary, Moorthy, Ganesh, primary, Mortimer, Peter G., primary, Moschetta, Michele, primary, Nikolaou, Myria, primary, Sainsbury, Liz, primary, Shapiro, Geoffrey I., primary, Siu, Lillian L., primary, and Hansen, Aaron R., primary

Published
2023
Full Text
View/download PDF

36. Supplementary Table 2 from Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate

Author

Attard, Gerhardt, primary, de Bono, Johann S., primary, Logothetis, Christopher J., primary, Fizazi, Karim, primary, Mukherjee, Som D., primary, Joshua, Anthony M., primary, Schrijvers, Dirk, primary, van den Eertwegh, Alfons J.M., primary, Li, Weimin, primary, Molina, Arturo, primary, Griffin, Thomas W., primary, Kheoh, Thian, primary, Ricci, Deborah S., primary, Zelinsky, Kathy, primary, Rathkopf, Dana E., primary, Scher, Howard I., primary, and Ryan, Charles J., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Data from A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors

Author

Choudhury, Atish D., primary, Higano, Celestia S., primary, de Bono, Johann S., primary, Cook, Natalie, primary, Rathkopf, Dana E., primary, Wisinski, Kari B., primary, Martin-Liberal, Juan, primary, Linch, Mark, primary, Heath, Elisabeth I., primary, Baird, Richard D., primary, García-Carbacho, Javier, primary, Quintela-Fandino, Miguel, primary, Barry, Simon T., primary, de Bruin, Elza C., primary, Colebrook, Steve, primary, Hawkins, George, primary, Klinowska, Teresa, primary, Maroj, Brijesh, primary, Moorthy, Ganesh, primary, Mortimer, Peter G., primary, Moschetta, Michele, primary, Nikolaou, Myria, primary, Sainsbury, Liz, primary, Shapiro, Geoffrey I., primary, Siu, Lillian L., primary, and Hansen, Aaron R., primary

Published
2023
Full Text
View/download PDF

39. Supplementary Figure 1 from Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone

Author

Rathkopf, Dana E., primary, Antonarakis, Emmanuel S., primary, Shore, Neal D., primary, Tutrone, Ronald F., primary, Alumkal, Joshi J., primary, Ryan, Charles J., primary, Saleh, Mansoor, primary, Hauke, Ralph J., primary, Bandekar, Rajesh, primary, Maneval, Edna Chow, primary, de Boer, Carla J., primary, Yu, Margaret K., primary, and Scher, Howard I., primary

Published
2023
Full Text
View/download PDF

40. Supplementary Table S2 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study

Author

Autio, Karen A., primary, Klebanoff, Christopher A., primary, Schaer, David, primary, Kauh, John Sae Wook, primary, Slovin, Susan F., primary, Adamow, Matthew, primary, Blinder, Victoria S., primary, Brahmachary, Manisha, primary, Carlsen, Michelle, primary, Comen, Elizabeth, primary, Danila, Daniel C., primary, Doman, Thompson N., primary, Durack, Jeremy C., primary, Fox, Josef J., primary, Gluskin, Jill S., primary, Hoffman, David M., primary, Kang, Suhyun, primary, Kang, Praneet, primary, Landa, Jonathan, primary, McAndrew, Philomena F., primary, Modi, Shanu, primary, Morris, Michael J., primary, Novosiadly, Ruslan, primary, Rathkopf, Dana E., primary, Sanford, Rachel, primary, Chapman, Sonya C., primary, Tate, Courtney M., primary, Yu, Danni, primary, Wong, Phillip, primary, and McArthur, Heather L., primary

Published
2023
Full Text
View/download PDF

41. Supplementary Figure 4 from Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate

Author

Attard, Gerhardt, primary, de Bono, Johann S., primary, Logothetis, Christopher J., primary, Fizazi, Karim, primary, Mukherjee, Som D., primary, Joshua, Anthony M., primary, Schrijvers, Dirk, primary, van den Eertwegh, Alfons J.M., primary, Li, Weimin, primary, Molina, Arturo, primary, Griffin, Thomas W., primary, Kheoh, Thian, primary, Ricci, Deborah S., primary, Zelinsky, Kathy, primary, Rathkopf, Dana E., primary, Scher, Howard I., primary, and Ryan, Charles J., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Figure from Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors

Author

Stopsack, Konrad H., primary, Nandakumar, Subhiksha, primary, Arora, Kanika, primary, Nguyen, Bastien, primary, Vasselman, Samantha E., primary, Nweji, Barbara, primary, McBride, Sean M., primary, Morris, Michael J., primary, Rathkopf, Dana E., primary, Slovin, Susan F., primary, Danila, Daniel C., primary, Autio, Karen A., primary, Scher, Howard I., primary, Mucci, Lorelei A., primary, Solit, David B., primary, Gönen, Mithat, primary, Chen, Yu, primary, Berger, Michael F., primary, Schultz, Nikolaus, primary, Abida, Wassim, primary, and Kantoff, Philip W., primary

Published
2023
Full Text
View/download PDF

43. Supplementary Figure S2 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study

Author

Autio, Karen A., primary, Klebanoff, Christopher A., primary, Schaer, David, primary, Kauh, John Sae Wook, primary, Slovin, Susan F., primary, Adamow, Matthew, primary, Blinder, Victoria S., primary, Brahmachary, Manisha, primary, Carlsen, Michelle, primary, Comen, Elizabeth, primary, Danila, Daniel C., primary, Doman, Thompson N., primary, Durack, Jeremy C., primary, Fox, Josef J., primary, Gluskin, Jill S., primary, Hoffman, David M., primary, Kang, Suhyun, primary, Kang, Praneet, primary, Landa, Jonathan, primary, McAndrew, Philomena F., primary, Modi, Shanu, primary, Morris, Michael J., primary, Novosiadly, Ruslan, primary, Rathkopf, Dana E., primary, Sanford, Rachel, primary, Chapman, Sonya C., primary, Tate, Courtney M., primary, Yu, Danni, primary, Wong, Phillip, primary, and McArthur, Heather L., primary

Published
2023
Full Text
View/download PDF

44. Supplementary Materials and Methods from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study

Author

Autio, Karen A., primary, Klebanoff, Christopher A., primary, Schaer, David, primary, Kauh, John Sae Wook, primary, Slovin, Susan F., primary, Adamow, Matthew, primary, Blinder, Victoria S., primary, Brahmachary, Manisha, primary, Carlsen, Michelle, primary, Comen, Elizabeth, primary, Danila, Daniel C., primary, Doman, Thompson N., primary, Durack, Jeremy C., primary, Fox, Josef J., primary, Gluskin, Jill S., primary, Hoffman, David M., primary, Kang, Suhyun, primary, Kang, Praneet, primary, Landa, Jonathan, primary, McAndrew, Philomena F., primary, Modi, Shanu, primary, Morris, Michael J., primary, Novosiadly, Ruslan, primary, Rathkopf, Dana E., primary, Sanford, Rachel, primary, Chapman, Sonya C., primary, Tate, Courtney M., primary, Yu, Danni, primary, Wong, Phillip, primary, and McArthur, Heather L., primary

Published
2023
Full Text
View/download PDF

45. Data from Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors

Author

Stopsack, Konrad H., primary, Nandakumar, Subhiksha, primary, Arora, Kanika, primary, Nguyen, Bastien, primary, Vasselman, Samantha E., primary, Nweji, Barbara, primary, McBride, Sean M., primary, Morris, Michael J., primary, Rathkopf, Dana E., primary, Slovin, Susan F., primary, Danila, Daniel C., primary, Autio, Karen A., primary, Scher, Howard I., primary, Mucci, Lorelei A., primary, Solit, David B., primary, Gönen, Mithat, primary, Chen, Yu, primary, Berger, Michael F., primary, Schultz, Nikolaus, primary, Abida, Wassim, primary, and Kantoff, Philip W., primary

Published
2023
Full Text
View/download PDF

46. Supplementary Table 3 from Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate

Author

Attard, Gerhardt, primary, de Bono, Johann S., primary, Logothetis, Christopher J., primary, Fizazi, Karim, primary, Mukherjee, Som D., primary, Joshua, Anthony M., primary, Schrijvers, Dirk, primary, van den Eertwegh, Alfons J.M., primary, Li, Weimin, primary, Molina, Arturo, primary, Griffin, Thomas W., primary, Kheoh, Thian, primary, Ricci, Deborah S., primary, Zelinsky, Kathy, primary, Rathkopf, Dana E., primary, Scher, Howard I., primary, and Ryan, Charles J., primary

Published
2023
Full Text
View/download PDF

47. Supplementary Table 1 from Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate

Author

Attard, Gerhardt, primary, de Bono, Johann S., primary, Logothetis, Christopher J., primary, Fizazi, Karim, primary, Mukherjee, Som D., primary, Joshua, Anthony M., primary, Schrijvers, Dirk, primary, van den Eertwegh, Alfons J.M., primary, Li, Weimin, primary, Molina, Arturo, primary, Griffin, Thomas W., primary, Kheoh, Thian, primary, Ricci, Deborah S., primary, Zelinsky, Kathy, primary, Rathkopf, Dana E., primary, Scher, Howard I., primary, and Ryan, Charles J., primary

Published
2023
Full Text
View/download PDF

48. First look at the baseline characteristics of participants in IRONMAN, the international registry for men with advanced prostate cancer.

Author

Mucci, Lorelei A, primary, Vinson, Jake, additional, Gerke, Travis A., additional, Hyslop, Terry, additional, Howard, Lauren, additional, Dreicer, Robert, additional, Rathkopf, Dana E., additional, Chi, Kim N., additional, Esteban, Emilio, additional, Enting, Deborah, additional, Bjartell, Anders, additional, Tagawa, Scott T., additional, Nanus, David M., additional, Ong, Michael, additional, Barata, Pedro C., additional, Hotte, Sebastien J., additional, Grant, Marie, additional, Villanti, Paul, additional, Kantoff, Philip W., additional, and George, Daniel J., additional

Published
2023
Full Text
View/download PDF

49. FORMULA-509: A multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with or without abiraterone acetate/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP).

Author

Nguyen, Paul L., primary, Kollmeier, Marisa, additional, Rathkopf, Dana E., additional, Hoffman, Karen E., additional, Zurita, Amado J., additional, Spratt, Daniel Eidelberg, additional, Dess, Robert Timothy, additional, Liauw, Stanley L., additional, Szmulewitz, Russell Zelig, additional, Einstein, David Johnson, additional, Bubley, Glenn, additional, Yu, James B., additional, An, Yi, additional, Wong, Anthony C., additional, Feng, Felix Y, additional, McKay, Rana R., additional, Rose, Brent S., additional, Shin, Kee-Young, additional, Kibel, Adam S., additional, and Taplin, Mary-Ellen, additional

Published
2023
Full Text
View/download PDF

50. Niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Second interim analysis (IA2) of MAGNITUDE.

Author

Efstathiou, Eleni, primary, Smith, Matthew Raymond, additional, Sandhu, Shahneen, additional, Attard, Gerhardt, additional, Saad, Marniza, additional, Olmos, David, additional, Castro, Elena, additional, Roubaud, Guilhem, additional, Gomes, Andrea Juliana, additional, Small, Eric Jay, additional, Rathkopf, Dana E., additional, Gurney, Howard, additional, Jung, Wonho, additional, Mason, Gary, additional, Francis, Peter St. John, additional, Wang, George C., additional, Wu, Daphne, additional, Diorio, Brooke, additional, Lopez- Gitlitz, Angela Mennicke, additional, and Chi, Kim N., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results